Ausgangsorgandysfunktion, die Standard Doxorubicin vorbeugt + ifosfamide (AI) neoadjuvant...

Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.

ID	`RF-MPNST-ORGAN-DYSFUNCTION`
Art	Warnhinweis
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Erkrankungen	`DIS-MPNST`
Quellen	`SRC-NCCN-SARCOMA`

Ursprung der Roten Flagge

Begriffsbestimmung	Baseline organ dysfunction precluding standard doxorubicin + ifosfamide (AI) neoadjuvant or salvage chemotherapy in MPNST: LVEF <50% (anthracycline contraindicated), CrCl <30 mL/min (ifosfamide nephrotoxicity), bilirubin >3× ULN (doxorubicin / ifosfamide hepatic metabolism), or DLCO <60% (post-thoracotomy reserve concern for pulmonary metastasectomy candidacy).
Klinische Richtung	Eskalation
Kategorie	Organdysfunktion

Logik auslösen

{
  "any_of": [
    {
      "comparator": "<",
      "finding": "lvef_percent",
      "threshold": 50
    },
    {
      "comparator": "<",
      "finding": "creatinine_clearance_ml_min",
      "threshold": 30
    },
    {
      "comparator": ">=",
      "finding": "bilirubin_ratio_to_uln",
      "threshold": 3
    },
    {
      "comparator": "<",
      "finding": "dlco_percent",
      "threshold": 60
    }
  ],
  "type": "lab_value"
}

Anmerkungen

AI is the soft-tissue sarcoma standard for high-grade MPNST in the preoperative setting (EORTC 62931 / 62012 data extrapolation). LVEF <50: substitute liposomal doxorubicin or omit anthracycline (ifosfamide + epirubicin or pazopanib alternative for advanced). CrCl <30: ifosfamide contraindicated — switch to dose-modified doxorubicin monotherapy. Pazopanib (PALETTE in non-MPNST STS) has limited but documented activity in MPNST — used in cisplatin / ifosfamide- ineligible. NF1-MPNST patients often have additional comorbidity (cardiomyopathy, scoliosis) lowering tolerance. DLCO <60: limits metastasectomy candidacy.

Verwendet von

Keine Rückverweise im YAML-Korpus gefunden.